Discrepant serological assays for Pneumococcus Pneumococcus in renal transplant recipients – a prospective study

摘要

Summary Vaccine immunoprotection for Streptococcus pneumoniae is mediated by opsonizing antibodies targeting serotype‐specific capsular polysaccharides. Quantitative antibody levels enzyme‐linked immunosorbent assay ( ELISA ) and antibody‐mediated opsonophagocytic assays ( OPA ) measure vaccine‐induced protection; correlation of these assays in transplantation requires investigation. This study examines the laboratory assessment of antibody titers in vaccinated renal recipients. Streptococcus pneumoniae 19A is common in immunocompromised hosts and is represented in protein‐conjugate vaccines ( PCV ) and polysaccharide vaccines ( PSV ). Antibodies to 19A in serial sera from 30 vaccinated renal transplant recipients were compared using ELISA and OPA assays. Subject titers were classified as protected or not by ELISA (0.35 μg/ml) and OPA titer (1:8). Antibody titers analyzed using McNemar's test indicate that protection measured by the two assays are not the same ( P = 0.0078); simple linear regression of within‐subject geometric means of 19A enzyme‐linked immunosorbent assay (ELISA) antibody levels versus 19A opsonophagocytic assays (OPA) titers demonstrates significant correlation between the two assays ( P 0.001). Vaccination is increasingly important given increasing antimicrobial resistance worldwide. OPA and ELISA antibody assays do not correlate well using current values for protective immunity against the Pneumococcus in immunosuppressed transplant recipients. Future studies of vaccination in transplant recipients should evaluate protective antibody levels using both functional antibody assays and standard ELISA antibody titers. (ClinicalTrials.gov: NCT00307125).